Edwards Lifesciences (EW) | Stock Overview & Key Data
Edwards Lifesciences Performance Comparison
Stock Range
Today's Range
Low: $74.51
High: $76.72
on October 2, 2025
52 Week Range
Low: $64.01
High: $83.00
on October 7, 2024
on July 25, 2025
All-Time High: $131.73 on December 27, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$45.7B
EPS
2.43
P/E Ratio (TTM)
31.40
Forward P/E
31.15
P/B Ratio
4.25
PEG Ratio
-4.79
Div. Yield
N/A
ROE
15.53%
Beta
1.070
Debt to Equity
6.62
Financial Highlights
Profitability
Gross Margin
77.52%
Operating Margin
28.12%
Profit Margin
72.96%
Returns and Earnings
Return on Assets (TTM)
8.42%
Return on Equity (TTM)
15.53%
EBITDA
$1.9B
Net Income (TTM)
$1.4B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$9.66
Quarterly Revenue Growth (YoY)
11.90%
Quarterly Earnings Growth (YoY)
-9.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Edwards Lifesciences EW | 45.70B Large-cap | 1.83% | -6.26% | -0.48% | 6.38% | 5.59% | 17.04% | -9.00% | -8.64% |
| Abbott Laboratories ABT | 231.60B Mega-cap | -0.24% | 1.16% | -0.84% | 0.80% | 17.23% | 18.07% | 30.65% | 21.29% |
| Boston Scientific BSX | 142.83B Large-cap | -1.96% | -9.79% | -7.15% | -3.83% | 7.65% | 13.82% | 142.00% | 133.88% |
| Stryker SYK | 139.22B Large-cap | -0.59% | -6.04% | -6.49% | -2.93% | 2.14% | 4.32% | 75.71% | 64.36% |
| Medtronic plc MDT | 121.93B Large-cap | 1.25% | 2.30% | 8.16% | 7.45% | 19.02% | 8.18% | 15.85% | -12.15% |
| Dexcom DXCM | 26.16B Large-cap | -2.72% | -10.58% | -20.51% | -2.49% | -15.36% | -2.45% | -34.95% | -31.15% |
Ownership & Short Interest
Insider Ownership
0.91%
Institutional Ownership
88.39%
Shares Short
7M
Short Ratio
1.86
Short % of Shares Outstanding
1.40%
Average 10-Day Volume
5M
Average 90-Day Volume
4M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is EW's 52-week high and low?
- In the last 52 weeks, Edwards Lifesciences reached a high of $83.00 (on July 25, 2025) and a low of $64.01 (on October 7, 2024).
- What is the market cap and P/E ratio for EW?
- Curious about Edwards Lifesciences's size and valuation? Its market capitalization stands at 45.70B. When it comes to valuation, the P/E ratio (trailing twelve months) is 31.40, and the forward P/E (looking ahead) is 31.15.
- Does EW pay dividends? If so, what's the yield?
- As for dividends, Edwards Lifesciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Edwards Lifesciences's main competitors or similar companies to consider before investing?
When looking at Edwards Lifesciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT231.60B Healthcare Medical Devices 18.07% 30.65% Boston Scientific
BSX142.83B Healthcare Medical Devices 13.82% 142.00% Stryker
SYK139.22B Healthcare Medical Devices 4.32% 75.71% Medtronic plc
MDT121.93B Healthcare Medical Devices 8.18% 15.85% Dexcom
DXCM26.16B Healthcare Medical Devices -2.45% -34.95% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Edwards Lifesciences Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Edwards Lifesciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 15.53%, the Debt to Equity ratio from the most recent quarter is 6.62, and its Gross Profit Margin stands at 77.52%.
- What is the recent revenue and earnings growth for EW?
- Looking at Edwards Lifesciences's growth, its revenue over the trailing twelve months (TTM) was $6B. Compared to the same quarter last year (YoY), quarterly revenue grew by 11.90%, and quarterly earnings saw a YoY growth of -9.00%.
- How much of EW stock is held by insiders and institutions?
- Wondering who owns Edwards Lifesciences stock? Company insiders (like executives and directors) hold about 0.91% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 88.39%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.